Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
2.
Urologiia ; (1): 42-6, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22646001

RESUMO

Patients with chronic prostatitis alone and in combination with prostatic adenoma have changes in the activity of the complement system, neutrophil function and content of pro- and anti-inflammatory cytokines. Abnormal representation of the proteins of the red cell membrane in patients with prostatic diseases affects structural and functional activity of erythrocytes in these patients. Dynamic changes in immune status of patients with chronic prostatitis and prostatic adenoma correlate with changes in functional red cell activity. This fact helps better understanding of pathogenesis of chronic prostatitis and prostatic adenoma.


Assuntos
Eritrócitos/imunologia , Eritrócitos/patologia , Doenças Prostáticas/sangue , Homeostase , Humanos , Masculino , Doenças Prostáticas/imunologia , Hiperplasia Prostática/sangue , Hiperplasia Prostática/imunologia , Neoplasias da Próstata/sangue , Neoplasias da Próstata/imunologia , Prostatite/sangue , Prostatite/imunologia
3.
Urologiia ; (4): 29-32, 2011.
Artigo em Russo | MEDLINE | ID: mdl-22066238

RESUMO

The aim of the study was detection of local and systemic changes in the complement system in patients with chronic abacterial prostatitis (CAP) and chronic bacterial prostatitis (CBP) and to assess a relevant corrective efficacy of the hardware and software complex Andro-Gin (KAP-ELM-01 Andro-Gin). Before treatment, blood plasma of CAP patients contained elevated concentrations of all studied components of the compliment system and factor H but subnormal concentration of C1-inhibitor. Locally, all the compliment indices were high including C1-inhibitor and factor H except component C5. Initial blood plasma compliment fractions in CBP patients were elevated but regulatory proteins concentrations were low. Local compliment components C3, C4, C5 and C5a and factor H were significantly higher. Standard treatment of CAP partially corrected the level of C3, C3a, C4 components, locally normalized concentration of C3 component and corrected C4 component, while in CBP standard treatment normalized concentration of C3 component and reduced C3a, C4, C5 and C5a components, locally normalized the levels of C3, C4 components, corrected concentration of C3a, C5, C5a components, raised regulatory factors. Combination of the standard treatment with Andro-Gin unit compared to standard treatment alone, in CAP corrected plasma concentrations of C3, C3a, C4 compliment components and significantly raised levels of regulatory factors, locally--partially normalized the level of factor H. In CBP additional use of Andro-Gin more significantly improved concentrations of C3a and C5a components , locally--C5a component, raised significantly concentration of regulatory factors C1-inhibitor and factor H. Thus, KAP-ELM-01 Andro-Gin administration in CAP and CBP patients promotes more effective correction of systemic and local disorders in the compliment system, the improvement being more pronounced in CBP.


Assuntos
Proteínas do Sistema Complemento/metabolismo , Terapia por Estimulação Elétrica/métodos , Terapia a Laser/métodos , Magnetoterapia/métodos , Prostatite/terapia , Doença Crônica , Terapia por Estimulação Elétrica/instrumentação , Humanos , Terapia a Laser/instrumentação , Magnetoterapia/instrumentação , Masculino , Prostatite/sangue , Prostatite/tratamento farmacológico , Prostatite/metabolismo , Resultado do Tratamento
4.
Urologiia ; (5): 39-42, 2011.
Artigo em Russo | MEDLINE | ID: mdl-22279785

RESUMO

Patients with chronic bacterial prostatitis were found to have disorders in blood parameters of complement system activity, neutrophil function and metabolic status. The above disorders are resistant to adequate correction with standard treatment but can be successfully managed with combined use ofimmunomodulators (ferrovir, galavit), antioxidants (mexidol, olifen) and membranoprotectors (phosphogliv, essentiale). Thus, immunometabolic status in chronic prostatitis can be corrected with the above combined treatment.


Assuntos
Antioxidantes/administração & dosagem , DNA/administração & dosagem , Compostos Férricos/administração & dosagem , Doenças do Sistema Imunitário/tratamento farmacológico , Fatores Imunológicos/administração & dosagem , Doenças Metabólicas/tratamento farmacológico , Éteres Fenílicos/administração & dosagem , Ftalazinas/administração & dosagem , Picolinas/administração & dosagem , Prostatite/tratamento farmacológico , Adulto , Humanos , Doenças do Sistema Imunitário/sangue , Doenças do Sistema Imunitário/complicações , Doenças do Sistema Imunitário/imunologia , Luminol/análogos & derivados , Masculino , Doenças Metabólicas/sangue , Doenças Metabólicas/complicações , Doenças Metabólicas/imunologia , Prostatite/sangue , Prostatite/complicações , Prostatite/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA